High-dose radiation-induced immunogenic cell death of bladder cancer cells leads to dendritic cell activation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 31 01 2024
accepted: 27 06 2024
medline: 4 9 2024
pubmed: 4 9 2024
entrez: 4 9 2024
Statut: epublish

Résumé

Radiotherapy is a commonly used method in the treatment of bladder cancers (BC). Radiation-induced immunogenic cell death (ICD) is related to the immune response against cancers and their prognoses. Even though dendritic cells (DC) act as powerful antigen-presenting cells in the body, their precise role in this ICD process remains unclear. Accordingly, an in vitro study was undertaken to ascertain whether high-dose radiation-induced ICD of BC cells could regulate the immune response of DC. The results indicated that high-dose radiation treatments of BC cells significantly increased their levels of apoptosis, blocked their cell cycle in the G2/M phase, increased their expression of ICD-related proteins, and upregulated their secretion of CCL5 and CCL21 which control the directed migration of DC. It was also noted that expression of CD80, CD86, CCR5, and CCR7 on DC was upregulated in the medium containing the irradiated cells. In conclusion, the present findings illustrate that high-dose radiation can induce the occurrence of ICD within BC cells, concomitantly resulting in the activation of DC. Such findings could be of great significance in increasing the understanding how radiotherapy of BC may work to bring about reductions in cell activity and how these processes in turn lead to immunoregulation of the function of DC.

Identifiants

pubmed: 39231199
doi: 10.1371/journal.pone.0307024
pii: PONE-D-24-01224
doi:

Substances chimiques

Chemokine CCL21 0
Receptors, CCR7 0
Chemokine CCL5 0
CCL21 protein, human 0
Receptors, CCR5 0
CCR7 protein, human 0
B7-2 Antigen 0
CCL5 protein, human 0
CCR5 protein, human 0
B7-1 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0307024

Informations de copyright

Copyright: © 2024 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Xianlin Zeng (X)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Daiqin Luo (D)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Shuai Zhang (S)

Department of Interventional Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Zhonghui Cui (Z)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Yun Wang (Y)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Jin Chen (J)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Shichao Zhang (S)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Lijing Teng (L)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Zuquan Hu (Z)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Lina Liu (L)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.

Shi Zhou (S)

Department of Interventional Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Zhu Zeng (Z)

School of Biology and Engineering/School of Basic Medical Sciences, Guizhou Medical University, Guiyang, China.
Engineering Center of Cellular Immunotherapy of Guizhou Province, Guiyang, China.
Key Laboratory of Infectious Immunity and Antibody Engineering of Guizhou Province, Guiyang, China.
Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education, Guizhou Medical University, Guiyang, China.
State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China.

Jinhua Long (J)

Department of Head and Neck, Affiliated Tumor Hospital of Guizhou Medical University, Guiyang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH